Hypertrophic Cardiomyopathy

High Prevalence and Clinical Impact of Sleep Apnea in Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort Study

By MedXY 09/27/2025

Sleep disordered breathing affects over half of patients with hypertrophic cardiomyopathy, correlating with worsening myocardial remodeling, diastolic dysfunction, and subclinical myocardial injury, underscoring the need for clinical trials on intervention.

Clinical Updates Wellness & Lifestyle

Unveiling the Genetic Complexity of Hypertrophic Cardiomyopathy: The Impact of Intermediate Effect Variants

By MedXY 09/07/2025

Intermediate effect genetic variants contribute significantly to hypertrophic cardiomyopathy risk and modify disease severity and outcomes, especially when coexisting with monogenic mutations.

Clinical Updates Wellness & Lifestyle

VO2 Recovery Time as a Novel Cardiac Performance Biomarker: Insights from the SEQUOIA-HCM Trial

By MedXY 09/05/2025

This article elucidates VO2T12.5% as a new, practical oxygen uptake recovery measure reflecting cardiac function and prognosis in heart failure and obstructive hypertrophic cardiomyopathy, validated in robust clinical cohorts including the SEQUOIA-HCM trial.

Clinical Updates Wellness & Lifestyle

Long-Term Benefits and Safety of Mavacamten in Obstructive Hypertrophic Cardiomyopathy: Insights from the VALOR-HCM 128-Week Study

By MedXY 08/17/2025

The VALOR-HCM trial demonstrates that mavacamten sustains symptomatic improvement and significantly reduces septal reduction therapy (SRT) need over 128 weeks in severely symptomatic obstructive hypertrophic cardiomyopathy patients.